CAJ | 학술논문

目的：分析吉非替尼对化疗后进展的晚期非小细胞肺癌患者的临床治疗效果。方法以我院2008年1月~2010年12月应用常规治疗的29例化疗后进展的晚期非小细胞肺癌患者为常规组，以我院同期加用吉非替尼治疗的29例患者为吉非替尼组，比较两组患者治疗后疾病控制率、中位生存时间及不良反应发生情况。结果吉非替尼组治疗后疾病控制率显著高于常规组，中位生存时间显著长于常规组，不良反应发生率显著低于常规组，两组各项数据经比较差异具有统计学意义，（P<0.05）。结论应用吉非替尼治疗化疗后进展的晚期非小细胞肺癌，患者治疗有效率显著提高，生存时间有所延长，安全可靠，值得临床推广应用。
목적：분석길비체니대화료후진전적만기비소세포폐암환자적림상치료효과。방법이아원2008년1월~2010년12월응용상규치료적29례화료후진전적만기비소세포폐암환자위상규조，이아원동기가용길비체니치료적29례환자위길비체니조，비교량조환자치료후질병공제솔、중위생존시간급불량반응발생정황。결과길비체니조치료후질병공제솔현저고우상규조，중위생존시간현저장우상규조，불량반응발생솔현저저우상규조，량조각항수거경비교차이구유통계학의의，（P<0.05）。결론응용길비체니치료화료후진전적만기비소세포폐암，환자치료유효솔현저제고，생존시간유소연장，안전가고，치득림상추엄응용。
Objective To analyze the progress of patients with advanced non-smal celllung cancer after chemotherapy in the clinical treatment ef ect. Methods From January 2008 to December 2010 between the application of conventional treatment of 29 cases progress of patients with advanced non-smal celllung cancer after chemotherapy for conventional group, the same period in our hospital and the treatment with the treatment for the treatment of 29 cases of patients group, compared two groups of patients after the disease control rates, the median survival time and adverse reactions occur. Results The treatment group after the disease control rates significantly higher than that of conventional group, the median survival time was significantly longer than the normal group, incidence of adverse reactions was significantly lower than normal group, two groups of data by comparing dif erences statistical y significant, (P < 0.05). Conclusion Gefitinib treatment progress of advanced non-smal celllung cancer after chemotherapy, ef ectively improve patient treatment, survival time was extended, safe and reliable, worthy of clinical popularization and application.